John H. Strickler

9.3k total citations · 2 hit papers
216 papers, 3.4k citations indexed

About

John H. Strickler is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, John H. Strickler has authored 216 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 170 papers in Oncology, 107 papers in Pulmonary and Respiratory Medicine and 45 papers in Cancer Research. Recurrent topics in John H. Strickler's work include Colorectal Cancer Treatments and Studies (98 papers), Lung Cancer Treatments and Mutations (52 papers) and Gastric Cancer Management and Outcomes (48 papers). John H. Strickler is often cited by papers focused on Colorectal Cancer Treatments and Studies (98 papers), Lung Cancer Treatments and Mutations (52 papers) and Gastric Cancer Management and Outcomes (48 papers). John H. Strickler collaborates with scholars based in United States, Japan and France. John H. Strickler's co-authors include Brent A. Hanks, Mustafa Khasraw, Tanios Bekaii‐Saab, Herbert I. Hurwitz, Bruce T. Liang, Kenneth A. Jacobson, Takayuki Yoshino, David S. Hong, James Trussell and Rosalie Dominik and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

John H. Strickler

201 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?

2020 267 citations John H. Strickler et al. Clinical Cancer Research profile →
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial

2024 49 citations Yasutoshi Kuboki, Marwan Fakih et al. Nature Medicine profile →

Peers

Countries citing papers authored by John H. Strickler

Since Specialization

Citations

This map shows the geographic impact of John H. Strickler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John H. Strickler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John H. Strickler more than expected).

Fields of papers citing papers by John H. Strickler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John H. Strickler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John H. Strickler. The network helps show where John H. Strickler may publish in the future.

Co-authorship network of co-authors of John H. Strickler

This figure shows the co-authorship network connecting the top 25 collaborators of John H. Strickler. A scholar is included among the top collaborators of John H. Strickler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John H. Strickler. John H. Strickler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase III study of perioperative dostarlimab in patients with dMMR/MSI-H resectable colon cancer: AZUR-2 study design 2026 ·Future Oncology ·Naureen Starling, (unknown), John H. Strickler, (unknown), Eiji Oki, Guillermo Ariel Mendez, (unknown), (unknown), (unknown), (unknown), (unknown), Daniel N. Cohen, (unknown), Neda Stjepanovic, Jenny F. Seligmann	0
2	Preparing for the Inevitable: Early Comprehensive Genomic Profiling for Patients With Localized Pancreatic Ductal Adenocarcinoma 2025 ·JCO Oncology Practice ·(unknown), Ryne C. Ramaker, (unknown), (unknown), Peter J. Allen, John H. Strickler, Daniel P. Nussbaum	0
3	A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with KRAS^G12D mutation. 2024 ·Journal of Clinical Oncology ·Amita Patnaik, Meredith Pelster, David S. Hong, John H. Strickler, Ignacio Garrido‐Laguna, Andrew J. Aguirre, (unknown), Tina M. Woo, Alexander I. Spira	6
4	Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER). 2024 ·Journal of Clinical Oncology ·John H. Strickler, Andrea Cercek, Salvatore Siena, Thierry André, (unknown), Eric Van Cutsem, Christina Wu, Andrew Scott Paulson, Joleen M. Hubbard, Andrew L. Coveler, Christos Fountzilas, Adel Kardosh, Pashtoon Murtaza Kasi, Heinz‐Josef Lenz, Kristen K. Ciombor, Élena Elez, David L. Bajor, (unknown), Wentao Feng, Tanios Bekaii‐Saab	2
5	Phase 1b study evaluating the efficacy and safety of ABBV-400, a c-Met–targeting antibody-drug conjugate, in select advanced solid tumor indications. 2024 ·Journal of Clinical Oncology ·Ruth Perets, Manish Sharma, John H. Strickler, Talia Golan, Antoine Hollebecque, (unknown), Athanasios Vasilopoulos, (unknown), (unknown), James J. Harding	0
6	First-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer. 2024 ·Journal of Clinical Oncology ·Manish Sharma, John H. Strickler, David Sommerhalder, Yasutoshi Kuboki, Ruth Perets, Jonathan Cohen, Judith Raimbourg, Takako Eguchi Nakajima, Noboru Yamamoto, Marcia Cruz‐Correa, Bert H. O’Neil, François Ghiringhelli, Kanwal Raghav, Rui Li, (unknown), (unknown), Kevin J. Freise, (unknown), Athanasios Vasilopoulos, John D. Powderly	9
7	Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial breakdown → 2024 ·Nature Medicine ·Yasutoshi Kuboki, Marwan Fakih, John H. Strickler, Rona Yaeger, Toshiki Masuishi, Edward Kim, Christine M. Bestvina, Scott Kopetz, Gerald S. Falchook, Corey J. Langer, John C. Krauss, Sonam Puri, (unknown), Emily Chan, (unknown), Lata Mukundan, Abraham Anderson, Qui Tran, David S. Hong	49
8	Association of Race and Ethnicity with Genomic Testing at a Comprehensive Cancer Center in North Carolina 2024 ·Cancer Research Communications ·Clare Meernik, (unknown), Yadurshini Raveendran, Michelle Green, Devon K. Check, Hayden B. Bosworth, Linda Sutton, John H. Strickler, Tomi Akinyemiju	2
9	Racial and ethnic disparities in genomic testing among lung cancer patients: a systematic review 2024 ·JNCI Journal of the National Cancer Institute ·Clare Meernik, Yadurshini Raveendran, Michala Kolarova, (unknown), (unknown), (unknown), (unknown), Stephanie Hendren, Hayden B. Bosworth, Devon K. Check, Michelle Green, John H. Strickler, Tomi Akinyemiju	5
10	Trastuzumab-Deruxtecan: Redefining HER2 as a Tumor Agnostic Biomarker 2024 ·Targeted Oncology ·(unknown), (unknown), John H. Strickler, Hampig Raphaël Kourié	5
11	Expansion of an Academic Molecular Tumor Board to Enhance Access to Biomarker-Driven Trials and Therapies in the Rural Southeastern United States 2024 ·Current Oncology ·(unknown), (unknown), (unknown), Elizabeth Maynard, (unknown), (unknown), Matthew McKinney, Linda Sutton, Shannon J. McCall, Michael Datto, (unknown), Bennett Adam Caughey, John H. Strickler, Ryne C. Ramaker	1
12	Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. 2023 ·Journal of Clinical Oncology ·Kanwal Raghav, Salvatore Siena, Atsuo Takashima, Takeshi Kato, Marc Van den Eynde, Maria Di Bartolomeo, Yoshito Komatsu, Hisato Kawakami, Marc Peeters, Thierry André, Sara Lonardi, Kensei Yamaguchi, Jeanne Tie, (unknown), John H. Strickler, Daniel Barrios, Qi Yan, Takahiro Kamio, Kojiro Kobayashi, Takayuki Yoshino	43
13	A Study to Learn how Well Tucatinib Plus Trastuzumab Works for Treating Participants with Metastatic Colorectal Cancer, and how Safe it is: A Plain Language Summary of the MOUNTAINEER Study 2023 ·Future Oncology ·John H. Strickler, Tanios Bekaii‐Saab	1
14	Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma 2021 ·Clinical Cancer Research ·D. Ross Camidge, Daniel Morgensztern, Rebecca S. Heist, Minal Barve, Everett E. Vokes, Jonathan W. Goldman, David S. Hong, Todd M. Bauer, John H. Strickler, Eric Angevin, Monica Motwani, Apurvasena Parikh, Zhaowen Sun, Bruce Allen Bach, Jun Wu, Philip Komarnitsky, Karen Kelly	60
15	Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University Experience 2021 ·JCO Precision Oncology ·Michelle Green, (unknown), (unknown), Shannon J. McCall, Matthew McKinney, (unknown), Carolyn S. Menendez, James L. Abbruzzese, John H. Strickler, Michael Datto	13
16	Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors 2020 ·Molecular Cancer Therapeutics ·John H. Strickler, Patricia LoRusso, Ravi Salgia, Yoon‐Koo Kang, (unknown), Chia‐Chi Lin, Peter Ansell, Monica Motwani, Shekman Wong, Huibin Yue, Lan Wang, Edward B. Reilly, Daniel Afar, Louie Naumovski, Ramesh K. Ramanathan	21
17	First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors 2018 ·Journal of Clinical Oncology ·John H. Strickler, Colin D. Weekes, John Nemunaitis, Ramesh K. Ramanathan, Rebecca S. Heist, Daniel Morgensztern, Eric Angevin, Todd M. Bauer, Huibin Yue, Monica Motwani, Apurvasena Parikh, Edward B. Reilly, Daniel Afar, Louie Naumovski, Karen Kelly	104
18	Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer 2017 ·Cancer Discovery ·John H. Strickler, Jonathan M. Loree, Leanne G. Ahronian, Aparna R. Parikh, Donna Niedzwiecki, Allan Andresson Lima Pereira, Matthew McKinney, W. Michael Korn, Chloé E. Atreya, Kimberly C. Banks, Rebecca J. Nagy, Funda Meric‐Bernstam, Richard B. Lanman, AmirAli Talasaz, Igor F. Tsigelny, Ryan B. Corcoran, Scott Kopetz	196
19	Development of a Novel c-MET–Based CTC Detection Platform 2016 ·Molecular Cancer Research ·Tian Zhang, Rengasamy Boominathan, Brad Foulk, Chandra Rao, Gabor Kemeny, John H. Strickler, James L. Abbruzzese, Michael R. Harrison, David S. Hsu, Patrick Healy, Jing Li, (unknown), (unknown), Carey Hobbs, (unknown), Daniel J. George, Herbert I. Hurwitz, Mark C. Connelly, Mariano A. García-Blanco, Andrew J. Armstrong	36
20	Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma 2008 ·Clinical Cancer Research ·Justin Kline, Ian E. Brown, (unknown), Christian U. Blank, John H. Strickler, (unknown), Long Zhang, Thomas F. Gajewski	79

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact